Thursday, October 15, 2026
BioNTech says BNT113 missed its progression-free survival goal
On October 13, 2026 BioNTech said the Phase 2/3 AHEAD-MERIT trial missed its progression-free survival goal for BNT113 plus pembrolizumab versus pembrolizumab alone in first-line unresectable recurrent or metastatic HPV16-positive head and neck cancer. An independent committee recommended the trial continue to overall survival, which can still count as a positive result under the pre-specified design. The company said it remains blinded to the ongoing data and did not publish a progression-free survival figure.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.
/ Related
- Health Canada authorizes BioNTech XFG Comirnaty shotSunday, September 20, 2026
- BioNTech combo posts 70 percent ORR in SCLCTuesday, September 15, 2026
- Gotistobart nearly doubles survival in squamous NSCLCMonday, September 14, 2026
- BioNTech halts Phase 2 colorectal cancer vaccine trialFriday, September 4, 2026